Background: Management of dual antiplatelet therapy (DAPT) in the perioperative setting is challenging, particularly in complex patient populations, such as those with underlying coagulopathy and/or recent percutaneous coronary interventions. Methods: In this case series, we describe the perioperative use of cangrelor bridge therapy in two patients undergoing liver transplantation after recent coronary drug-eluting stent placement. Outcomes: In both patient cases, cangrelor use as a P2Y12 bridge at a dose of 0.75 μg/kg/min was safe and effective. Both patients were successfully switched back to their oral DAPT regimen post-operatively without additive bleeding or thrombotic complications. Conclusion: The use of cangrelor as bridge therapy in high-risk perioperative liver transplant patients appears to be a viable option when DAPT is warranted.

Original languageEnglish (US)
Pages (from-to)263-267
Number of pages5
Issue number3
Early online dateJan 25 2022
StatePublished - Mar 2022


  • cangrelor
  • dual antiplatelet therapy (DAPT)
  • liver transplant
  • perioperative
  • Adenosine Monophosphate/analogs & derivatives
  • Percutaneous Coronary Intervention/adverse effects
  • Drug-Eluting Stents
  • Liver Transplantation
  • Humans
  • Platelet Aggregation Inhibitors
  • Treatment Outcome
  • Drug Therapy, Combination

ASJC Scopus subject areas

  • Pharmacology (medical)


Dive into the research topics of 'Perioperative cangrelor in patients with recent percutaneous coronary intervention undergoing liver transplantation: A case series'. Together they form a unique fingerprint.

Cite this